Aurora kinases expression and possible cancer risk indicator in individuals with diabetes melittus type 2
International Journal of Development Research
Aurora kinases expression and possible cancer risk indicator in individuals with diabetes melittus type 2
Received 10th August, 2021; Received in revised form 17th August, 2021; Accepted 03rd September, 2021; Published online 30th September, 2021
Copyright © 2021, Mariana Neves Tavares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We aimed to verify the genomic instability in type 2 diabetes mellitus (DM2) by comparing the levels of AURKA and AURKB expression, commonly hyperexpressed in many tumors, in addition to the TP53 deletion status. Peripheral blood samples from 76 individuals, being 36 samples from individuals with DM2 and 40 samples from health donors were used. Significant differences were observed (AURKA: 2.013 ± 0.322 versus 1.126 ± 0.217, p < 0.0001, in DM2 versus health donors) and (AURKB: 1.600 ± 0.113 versus 1.133 ± 0.121, p < 0.0001, in DM2 versus health donors). All results were confirmed by FISH. Regarding the TP53 status, only 19 individuals (52,7%), from DM2 group, showed TP53 deletion. Although the over expression of aurora kinase genes presents an oncogenic potential, it is not possible to conclude that an increase in the expression of these genes would necessarily lead to the development of a neoplasm in these patients. However, our results suggest that some individuals in the DM2 may have higher risk for genomic instability.
